TEVA
After a long and enduring bidding battle between pharmaceutical giants and Goliaths that started off last year in the month of November between about twelve various firms from across the globe, TEVA (from the state of Israel) has sealed the competition for acquiring German pharma giant Ratiopharm after it gained ownership rights to the latter for a colossal sum of three point six two five billion Euros.
In the last phase of the bidding battle, TEVA faced competition (and a possible threat) from only two other drug manufacturers who possessed the right kind of financial strength to have acquired Ratiopharm; Pfizer from the United States of America and Actavis from the state of Iceland. With Ratiopharm added to its already existing and vibrant revenue portfolio, the officials at TEVA said that the combined revenue would easily penetrate the sixteen billion US dollars mark. The famous Merckle coven from the state of Germany put up Ratiopharm for bidding to sail their financial empire out of troubled waters.
In addition to the multiplied revenues, another major advantage that TEVA will get to enjoy with the obtaining of Ratiopharm is that its national rating in the state of Germany will be boosted up to the 2nd spot down from the 4th spot. This boost in national ranking will open new venues of investment for the Israeli drug giant and is hoped to be well received by the general public and the business community alike. The global share will go up to nineteen percent as well.
TEVA
Related posts:
- AstraZeneca ...
- Maxine Waters ...
- Allegheny Energy ...
- General Growth Properties ...
- PA Lottery ...
Related posts brought to you by Yet Another Related Posts Plugin.
